Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | BIO-WORKS TECHNOLOGIES AB: Today is the first day of the third exercise period for Bio-Works Technologies AB's warrants of series TO 2 | 2 | Cision News | ||
15.05. | BIO-WORKS TECHNOLOGIES AB: Bio-Works receives WorkBeads order worth SEK 2.5 million | 1 | Cision News | ||
15.05. | BIO-WORKS TECHNOLOGIES AB: Resolutions passed at Bio-Works Technologies' annual general meeting 2025 | 16 | Cision News | ||
15.05. | BIO-WORKS TECHNOLOGIES AB: Bio-Works reports first quarter 2025 | 1 | Cision News | ||
29.04. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Receives Order Worth SEK 2.4 Million from New European Customer in Vaccine Production | 1 | Cision News | ||
15.04. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB announces outcome from exercise of warrants of series TO 2. Exercise period 2 of 11 | 1 | Cision News | ||
14.04. | BIO-WORKS TECHNOLOGIES AB: Bio-Works receives SEK 12 million order from global pharmaceutical company - delivery scheduled for 2026 | 3 | Cision News | ||
01.04. | BIO-WORKS TECHNOLOGIES AB: Today is the first day of the second exercise period for Bio-Works Technologies AB's warrants of series TO 2 | 2 | Cision News | ||
BIO-WORKS TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
27.03. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Receives New Orders for Custom GoBio Columns for the U.S. Gene Therapy Market | 2 | Cision News | ||
26.02. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Receives Order for WorkBeads Worth 2.65 Million SEK | 2 | Cision News | ||
21.02. | BIO-WORKS TECHNOLOGIES AB: Bio-Works publishes year-end report Q4 2024 | 1 | Cision News | ||
14.02. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies Doubles Production Capacity to Meet Growing Demand | 5 | Cision News | ||
10.02. | BIO-WORKS TECHNOLOGIES AB: Bio-Works receives a third follow-up order for WorkBeads affimAb worth SEK 4.0 million | 1 | Cision News | ||
31.01. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Receives Follow-Up Order for WorkBeads affimAb Worth 4.6 MSEK | 1 | Cision News | ||
14.01. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Confirms a New Order for WorkBeads affimAb for Use in Antibody Production for 11.2 MSEK | 1 | Cision News | ||
07.08.24 | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.08.2024 | 1.062 | Xetra Newsboard | Das Instrument LY10 AU000000LLO8 LION ONE METALS CDIS EQUITY wird cum Kapitalmassnahme gehandelt am 07.08.2024 und ex Kapitalmassnahme am 08.08.2024 The instrument LY10 AU000000LLO8 LION ONE METALS... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 40,740 | -1,31 % | Kurs von Qiagen NV steigt etwas (41,29 €) | Am Aktienmarkt notiert der Anteilsschein von Qiagen NV derzeit ein wenig fester. Zuletzt zahlten Investoren für das Wertpapier 41,29 Euro. Heute hat sich im Wertpapierhandel die Qiagen NV-Aktie zwischenzeitlich... ► Artikel lesen | |
NUVALENT | 80,50 | 0,00 % | Goldman Sachs nimmt Nuvalent-Aktie mit Kaufempfehlung in die Bewertung auf | ||
RECURSION PHARMACEUTICALS | 5,210 | 0,00 % | Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process? | ||
EVOTEC | 7,350 | +1,38 % | Evotec, Lanxess, Northern Data, Redcare Pharmacy, Renk Group, Vonovia - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
CG ONCOLOGY | 26,680 | +1,25 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
BEAM THERAPEUTICS | 19,890 | 0,00 % | H.C. Wainwright bekräftigt Kaufempfehlung für Beam Therapeutics mit Kursziel von 80 US-Dollar | ||
ENLIVEN THERAPEUTICS | 20,640 | +5,04 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress | Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent... ► Artikel lesen | |
TREVI THERAPEUTICS | 5,980 | 0,00 % | Cantor Fitzgerald initiates coverage on Trevi Therapeutics stock with Overweight rating | ||
PHATHOM PHARMACEUTICALS | 8,910 | 0,00 % | Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 22,650 | 0,00 % | Revolution Medicines, Inc.: Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors | REDWOOD CITY, Calif. and MIAMI, June 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with... ► Artikel lesen | |
EDGEWISE THERAPEUTICS | 13,010 | +1,48 % | Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies | - New open label data in Becker demonstrated sustained disease stabilization up to three years, reinforcing prior clinical findings -- Ongoing pivotal trial and FDA Type C meeting provide... ► Artikel lesen | |
TANGO THERAPEUTICS | 5,650 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung ... | BOSTON, June 27, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines... ► Artikel lesen | |
IMMUNOME | 8,630 | 0,00 % | Immunome Inc. - 8-K, Current Report | ||
HARMONY BIOSCIENCES | 32,110 | 0,00 % | Pre-market Movers: Alti Global, CXApp, PAM Transportation Services, Harmony Biosciences, iCoreConnect | ROME (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 09.15 A.M. ET).In the Green CXApp Inc (CXAI) is up over 37% at $1.11.
PAM Transportation... ► Artikel lesen | |
SANA BIOTECHNOLOGY | 2,920 | 0,00 % | Morgan Stanley initiates Sana Biotechnology stock with Overweight rating |